Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 16

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 16
---
 |          |     |  4.9 | % |     |     |  0.7 | %                         |
| Core research and development (R&D) expenses             |     |                           |     |      |   -729.6 |     |                  |     |   -730.4 |     |          |     |   -0.7 |     |          |     |  0.1 | % |     |     | -4.4 | %                         |
| Core operating profit                                    |     |                           |     |      |  1,054.9 |     |                  |     |  1,162.6 |     |          |     |  107.8 |     |          |     | 10.2 | % |     |     |  4.9 | %                         |

During the periods presented, these items fluctuated as follows:

#### Core Cost of Sales
Core Cost of Sales was JPY 1,581.8 billion (JPY +155.5 billion and +10.9% AER, +6.6% CER). The increase was primarily due to revenue growth in our key business areas with a change in product mix and the depreciation of the Japanese yen as compared to the fiscal year ended March 31, 2024.

<div align='center'>7</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Fiscal Year

Ended March 31, 2025 (Consolidated)

Core Selling, General and Administrative (SG&A) Expenses

Core SG&A Expenses were JPY 1,105.0 billion (JPY +52.1 billion and +4.9% AER, +0.7% CER). The increase was mainly due to the depreciation of the Japanese yen, with efficiency gains largely offsetting incremental investments in Data, Digital and Technology (“DD&T”) and the impact of inflation.

#### Core Research and Development (R&D) Expenses
Core R&D Expenses were JPY 730.4 billion (JPY +0.7 billion and +0.1% AER, -4.4% CER), essentially flat compared to the fiscal year ended March 31, 2024, reflecting the depreciation of the Japanese yen offset by lower expenses attributable to efficiency gains and termination of development programs in the fiscal year ended March 31, 2024, such as modakaf